Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Net Cash Flow (2016 - 2025)

Historic Net Cash Flow for Catalyst Pharmaceuticals (CPRX) over the last 16 years, with Q3 2025 value amounting to $37.1 million.

  • Catalyst Pharmaceuticals' Net Cash Flow fell 4433.81% to $37.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $247.6 million, marking a year-over-year decrease of 2296.46%. This contributed to the annual value of $379.9 million for FY2024, which is 33632.7% up from last year.
  • Per Catalyst Pharmaceuticals' latest filing, its Net Cash Flow stood at $37.1 million for Q3 2025, which was down 4433.81% from $72.1 million recorded in Q2 2025.
  • In the past 5 years, Catalyst Pharmaceuticals' Net Cash Flow ranged from a high of $172.8 million in Q1 2024 and a low of -$150.1 million during Q1 2023
  • Moreover, its 5-year median value for Net Cash Flow was $30.5 million (2023), whereas its average is $29.0 million.
  • Its Net Cash Flow has fluctuated over the past 5 years, first soared by 85136.32% in 2021, then crashed by 226757.62% in 2023.
  • Over the past 5 years, Catalyst Pharmaceuticals' Net Cash Flow (Quarter) stood at $16.6 million in 2021, then skyrocketed by 154.86% to $42.3 million in 2022, then tumbled by 60.63% to $16.7 million in 2023, then skyrocketed by 351.38% to $75.2 million in 2024, then tumbled by 50.69% to $37.1 million in 2025.
  • Its Net Cash Flow was $37.1 million in Q3 2025, compared to $72.1 million in Q2 2025 and $63.1 million in Q1 2025.